| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Date of Report (Date of earliest event reported): November 16, 2026 |
| 16 Nov 2026 | 10-Q |
| 13 Oct 2026 | ARS |
| 13 Oct 2026 | DEFA14A |
| 13 Oct 2026 | Proxy statement: annual meeting on December 3, 2026 |
| 02 Oct 2026 | PRE 14A |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the th... |
| 14 Aug 2026 | 10-Q |
| 04 Aug 2026 | SCHEDULE 13D/A |
| 04 Aug 2026 |
Form 4: Uihlein Richard E, Director
Received 34,376,167 shares by exercise or conversion ($106M) |
| 04 Aug 2026 |
8-K: Unregistered Sales of Equity Securities
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock |
| 16 Jul 2026 |
Form 4: Jamil Khurram, Chief Medical Officer
Received 16,250 shares by exercise or conversion ($49.4K) · Sold 16,250 shares ($83.3K) |
| 30 Jun 2026 |
Form 4: Shlevin Harold H., Director
Received 7,732 shares by exercise or conversion ($9.51K) · Sold 7,732 shares ($38.7K) · Received 22,268 shares by exercise or conversion ($27.4K) · 1 more |
| 30 Jun 2026 |
Form 4: Jamil Khurram, Chief Medical Officer
Received 4,570 shares by exercise or conversion ($10.8K) · Sold 4,570 shares ($22.9K) · Received 47,467 shares by exercise or conversion ($119K) · 1 more |
| 29 Jun 2026 | 144 |
| 26 Jun 2026 | 144 |
| 26 Jun 2026 | 144 |
| 25 Jun 2026 |
Form 4: Jamil Khurram, Chief Medical Officer
Received 7,557 shares by exercise or conversion ($9.3K) · Sold 7,557 shares ($23.7K) |
| 23 Jun 2026 | 144 |
| 23 Jun 2026 |
8-K: Regulation FD Disclosure
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension |
Loading...